Phase I/IIa study of low dose subcutaneous interleukin-2 (IL-2) for treatment of refractory chronic graft versus host disease

Takeru Asano, Ken Ichi Matsuoka, Satoshi Iyama, Kazuteru Ohashi, Yoshihiro Inamoto, Chikako Ohwada, Makoto Murata, Atsushi Satake, Chikamasa Yoshida, Koichi Nakase, Yasuo Mori, Mitsune Tanimoto

研究成果: ジャーナルへの寄稿学術誌査読

5 被引用数 (Scopus)

抄録

Chronic graft versus host disease (cGVHD) remains a major problem for long survivors after allogeneic hematopoietic stem cell transplantation (HSCT). Currently, corticosteroid therapy is effective for cGVHD as the first line therapy. However, prolonged therapy with corticosteroids causes various severe adverse events. To develop the new therapeutic strategy of cGVHD, we have launched a multicenter phase I/IIa clinical trial of low dose subcutaneous interleukin-2 (IL-2) for treatment of steroid refractory cGVHD, which is constituted of 2 sequential phases (induction phase and maitanance phase). This study will provide the new therapeutic option for patients with refractory cGVHD after allogeneic HSCT.

本文言語英語
ページ(範囲)429-433
ページ数5
ジャーナルActa medica Okayama
70
5
出版ステータス出版済み - 2016

!!!All Science Journal Classification (ASJC) codes

  • 生化学、遺伝学、分子生物学(全般)

フィンガープリント

「Phase I/IIa study of low dose subcutaneous interleukin-2 (IL-2) for treatment of refractory chronic graft versus host disease」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル